CDKN2A and neoplasm: Adib et al. [63] found that patients with cdkn2a -altered urothelial cancer had decreased pd-l1 expression in tumor-infiltrating immune cells, as well as decreased T cell receptors, antigen processing, and activation of interferon-gamma pathways.